Lineage Cell Therapeutics Inc (LCTX)vsVertex Pharmaceuticals Inc (VRTX)
LCTX
Lineage Cell Therapeutics Inc
$1.03
0.00%
HEALTHCARE · Cap: $268.08M
VRTX
Vertex Pharmaceuticals Inc
$508.34
-1.55%
HEALTHCARE · Cap: $130.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 96110% more annual revenue ($12.59B vs $13.08M). VRTX leads profitability with a 35.0% profit margin vs -246.6%. VRTX appears more attractively valued with a PEG of 1.89. VRTX earns a higher WallStSmart Score of 64/100 (C+).
LCTX
Avoid18
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+84.3%
Fair Value
$11.43
Current Price
$1.03
$10.40 discount
Margin of Safety
+46.3%
Fair Value
$960.82
Current Price
$508.34
$452.48 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LCTX
The strongest argument for LCTX centers on Debt/Equity.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : LCTX
The primary concerns for LCTX are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
LCTX profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.
LCTX carries more volatility with a beta of 1.55 — expect wider price swings.
VRTX is growing revenue faster at 12.5% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 18/100), backed by strong 35.0% margins and 12.5% revenue growth. LCTX offers better value entry with a 84.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage Cell Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the United States and internationally. The company is headquartered in Carlsbad, California.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?